FI930846A - HOMOCONJUGERADE IMMUNOGLOBULINER - Google Patents

HOMOCONJUGERADE IMMUNOGLOBULINER Download PDF

Info

Publication number
FI930846A
FI930846A FI930846A FI930846A FI930846A FI 930846 A FI930846 A FI 930846A FI 930846 A FI930846 A FI 930846A FI 930846 A FI930846 A FI 930846A FI 930846 A FI930846 A FI 930846A
Authority
FI
Finland
Prior art keywords
immunoglobuliner
homoconjugerade
homoconjugerade immunoglobuliner
Prior art date
Application number
FI930846A
Other languages
Finnish (fi)
Other versions
FI930846A0 (en
Inventor
Edith Ann Wolff
Howard V Raff
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI930846A0 publication Critical patent/FI930846A0/en
Publication of FI930846A publication Critical patent/FI930846A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI930846A 1990-08-31 1993-02-25 HOMOCONJUGERADE IMMUNOGLOBULINER FI930846A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57572590A 1990-08-31 1990-08-31
US74866291A 1991-08-26 1991-08-26
PCT/US1991/006195 WO1992004053A1 (en) 1990-08-31 1991-08-29 Homoconjugated immunoglobulins

Publications (2)

Publication Number Publication Date
FI930846A0 FI930846A0 (en) 1993-02-25
FI930846A true FI930846A (en) 1993-04-05

Family

ID=27076774

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930846A FI930846A (en) 1990-08-31 1993-02-25 HOMOCONJUGERADE IMMUNOGLOBULINER

Country Status (11)

Country Link
EP (1) EP0547137A4 (en)
JP (1) JPH06500780A (en)
KR (1) KR930702029A (en)
AU (1) AU8506991A (en)
CA (1) CA2090317A1 (en)
FI (1) FI930846A (en)
IE (1) IE913071A1 (en)
IL (1) IL99363A0 (en)
NZ (1) NZ239617A (en)
PT (1) PT98840A (en)
WO (1) WO1992004053A1 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281300A (en) * 1993-08-26 1995-03-01 Merck & Co Inc Anti-HIV antibody oligomer
US6368596B1 (en) * 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
KR101027427B1 (en) 2004-11-12 2011-04-11 젠코어 인코포레이티드 Fc VARIANTS WITH INCREASED BINDING TO FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JP4860703B2 (en) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド Optimized anti-CD30 antibody
ES2402591T3 (en) 2006-08-14 2013-05-07 Xencor Inc. Optimized antibodies that target CD19
EP2064240A2 (en) 2006-09-18 2009-06-03 Xencor, Inc. Optimized antibodies that target hm1.24
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
EP2417159A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-3/anti-c-met antibodies
JP5616428B2 (en) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト Trivalent bispecific antibody
KR20110124368A (en) 2009-04-07 2011-11-16 로슈 글리카트 아게 Bispecific anti-erbb-2/anti-c-met antibodies
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
JP5758004B2 (en) 2010-08-24 2015-08-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Bispecific antibodies comprising Fv fragments stabilized by disulfides
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112014019579A2 (en) 2012-02-10 2019-10-15 Genentech, Inc SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION
SG11201406238UA (en) 2012-04-05 2014-10-30 Hoffmann La Roche Bispecific antibodies against human tweak and human il17 and uses thereof
BR112014028368A2 (en) 2012-06-27 2017-11-14 Hoffmann La Roche method of producing antibody fc region conjugate, antibody fc region conjugate and pharmaceutical formulation
ES2597228T3 (en) 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedure for the selection and production of objectification entities, such as targets, highly selective and multi-specific, customized, which contain at least two different binding entities, and use of these
EP2869837B1 (en) 2012-07-04 2016-09-14 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
EP3339328A1 (en) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
BR112014029403A2 (en) 2012-07-04 2018-10-09 F. Hoffmann-La Roche Ag conjugates, antibody and pharmaceutical formulation
CN104341504B (en) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 Bispecific antibody
PT3083680T (en) 2013-12-20 2020-03-17 Hoffmann La Roche Humanized anti-tau(ps422) antibodies and methods of use
CN105873615B (en) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
BR112016013849A2 (en) 2014-01-03 2017-10-10 Hoffmann La Roche bispecific antihapten / blood-brain barrier receptor conjugates, their uses, and pharmaceutical formulation
JP6521464B2 (en) 2014-01-03 2019-05-29 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Covalently linked polypeptide toxin-antibody conjugates
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
CN107810196B (en) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 Humanized anti-Tau (pS422) antibodies and methods of use
CA3081560A1 (en) * 2017-11-07 2019-05-16 Hubit Genomix, Inc. Method for primary prevention of allergic disorders during infancy through ige-class-specific immunosuppression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422653D0 (en) * 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
AU648056B2 (en) * 1989-11-07 1994-04-14 Bristol-Myers Squibb Company Oligomeric immunoglobulins

Also Published As

Publication number Publication date
FI930846A0 (en) 1993-02-25
KR930702029A (en) 1993-09-08
AU8506991A (en) 1992-03-30
PT98840A (en) 1992-07-31
JPH06500780A (en) 1994-01-27
NZ239617A (en) 1993-11-25
EP0547137A4 (en) 1993-12-08
IE913071A1 (en) 1992-03-11
WO1992004053A1 (en) 1992-03-19
IL99363A0 (en) 1992-08-18
EP0547137A1 (en) 1993-06-23
CA2090317A1 (en) 1992-03-01

Similar Documents

Publication Publication Date Title
NO924798D0 (en) HAARFORMINGSSJAMPOER
ATA150090A (en) HOERGERAET
FI930846A (en) HOMOCONJUGERADE IMMUNOGLOBULINER
FI925594A0 (en) FOTOGRAFISERIE
FI930878A (en) A-SUBSTITUERADE TRYPTOFAN-DIPEPTOIDDERIVAT
FI925980A (en) BISHETEROCYCLISKA FOERENINGAR
ATA210290A (en) LOTPILLE
FI931157A0 (en) 5-TRIFLUORACYLAMINO-2-ARYLOXATZOLER
FI924890A0 (en) HYBRIDCELLRECEPTOR
FI931749A (en) NYTT ISOMERISATIONSENZYM
ATA80690A (en) ALPINSCHI
FI84789C (en) FAESTSYSTEM OCH -ANORDNING
ATA200090A (en) PIANINO
ATA237490A (en) RINNENSTEIN
ATA209290A (en) DIARAEHMCHEN
FI924460A0 (en) HMG-COA-REDUCTIVE INHIBITORER
NO178511C (en) Presstörke
FI930896A0 (en) ENSILAGETILLSATS
BR7001930U (en) TERRARIO
BR7000495U (en) LIFE-BREAKER
BR7002566U (en) ALUVIONAR MINERATOR
BR7002265U (en) TRUMB
BR7001933U (en) PULALASTIC
BR7002609U (en) CAMELOMOVEL
BR7001859U (en) PROTELETRON